Avacta Therapeutics presented preclinical data on its dual payload technology at a cancer conference, showcasing its ability to deliver two therapeutic payloads to the tumor microenvironment simultaneously. The company’s innovative approach aims to address resistance mechanisms in cancer cells and maximize therapeutic effect through targeted combination delivery. The technology has the potential to significantly improve outcomes for cancer patients, particularly those with highly-resistant tumors. The pre|CISION® platform has been validated with compelling clinical data, demonstrating its ability to release two drugs from one molecule to target resistant cancers.
The pre|CISION® dual payload technology demonstrated FAP-selective delivery, potent anti-tumor activity, and robust biomarker modulation in preclinical findings. The technology showed enhanced synergistic activity in addressing resistance mechanisms and a bystander effect in physiologically relevant 3D models. Avacta’s approach to dual payload cancer therapies offers advantages over traditional delivery methods, including tumor-specific payload release and better tumor penetration. The company’s poster presentation on the technology is available on their website, with a webinar scheduled to discuss the data further.

Read more at GlobeNewswire: Avacta presents first preclinical data from dual payload